Aclarion Inc (ACON) Stock Price, Quote & News

Company Profile

Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs whi...

Industry: Health Information Services

Sector: Healthcare

Phone: 833 275 2266

Website: www.aclarion.com

Address:

8181 Arista Place, Suite 100, Broomfield, United States

TurskaInTar Dec. 4 at 8:20 PM

$ACON close the gap already 😂 Going up anyway imo

0 · Reply

Pinecone_Tradingz_ Dec. 4 at 4:41 PM

Banked up $8.4K profits on that run! Thank you! Made my whole month! Make sure you FOLLOW @ICEMAN_ALERTS below, Great trader!! He's been on fire recently, Keeping my port green 🙏 🔥 Adding more $ACON $EOSE $IBIO $BETR also !

0 · Reply

Putnik Dec. 4 at 4:08 PM

$ACON come on move for real!

0 · Reply

TurskaInTar Dec. 4 at 3:51 PM

$ACON $16 cash/share

0 · Reply

TurskaInTar Dec. 4 at 3:21 PM

$ACON SP should be double at least at this point, tech is working and teh market and the need is huge. And they have cash to make this work without new offerings.

0 · Reply

brptrader Dec. 4 at 3:13 PM

$ACON so some one or sombodies drove this to shit yesterday knowing news was coming out today...Nothing to see here, keep moving.

0 · Reply

TurskaInTar Dec. 4 at 3:06 PM

$ACON Publication in IJSS should speed up adaptation and expansion, and seems they are ready for it. Payer coverages for example with AXA has been in order for some time and so on...

0 · Reply

topstockalerts Dec. 4 at 2:58 PM

Aclarion said its Nociscan solution was highlighted in the International Journal of Spine Surgery’s Special Pain Edition. The company uses biomarkers and AI to help pinpoint sources of chronic lower back pain, and the article—sponsored by Aclarion—featured a case where Nociscan guided a surgeon to treat one disc instead of two, leading to full pain relief and recovery for a 27-year-old patient. Aclarion called the recognition meaningful given the journal’s scientific reputation. Nociscan is described as the first science-supported SaaS platform enabling noninvasive differentiation between painful and nonpainful lumbar discs, targeting an estimated 266 million chronic back-pain sufferers worldwide. $ACON

0 · Reply

TurskaInTar Dec. 4 at 2:55 PM

$ACON and after eight comes nine if I remember right

0 · Reply

TurskaInTar Dec. 4 at 2:36 PM

$ACON https://aclarion.com/aclarion-announces-publication-of-nociscan-article-in-special-pain-issue-of-the-international-journal-of-spine-surgery-ijss/

0 · Reply

Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)

Dec 2, 2025, 8:00 AM EST - 2 days ago

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Oct 22, 2025, 6:00 AM EDT - 6 weeks ago

Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Oct 9, 2025, 6:00 AM EDT - 2 months ago

Aclarion to Present at the LD Micro Main Event XIX

Jun 24, 2025, 7:00 AM EDT - 5 months ago

Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum

May 20, 2025, 6:00 AM EDT - 7 months ago

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

May 12, 2025, 7:34 AM EDT - 7 months ago

Aclarion Announces Texas Back Institute as New CLARITY Trial Site

Apr 29, 2025, 6:00 AM EDT - 7 months ago

Aclarion Announces Commercial Agreement with Spine Institute of Louisiana

Apr 23, 2025, 6:00 AM EDT - 8 months ago

Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025

Apr 21, 2025, 6:00 AM EDT - 8 months ago

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

Apr 9, 2025, 7:00 AM EDT - 8 months ago

Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub

Apr 2, 2025, 6:00 AM EDT - 8 months ago

Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California

Mar 31, 2025, 7:00 AM EDT - 8 months ago

Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives

Mar 13, 2025, 9:25 AM EDT - 9 months ago

Aclarion Provides Shareholder Update

Mar 6, 2025, 9:35 AM EST - 9 months ago

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

Mar 3, 2025, 6:00 AM EST - 9 months ago

Aclarion Announces First Commercial Agreement with Scripps Health

Feb 20, 2025, 6:00 AM EST - 10 months ago

Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit

Feb 11, 2025, 7:58 AM EST - 10 months ago

Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body

Feb 6, 2025, 7:23 AM EST - 10 months ago

Aclarion Announces Northwestern Medicine as First CLARITY Trial Site

Feb 4, 2025, 7:23 AM EST - 10 months ago

Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded

Nov 21, 2024, 8:00 AM EST - 1 year ago

Aclarion Announces Nociscan Featured in RSNA Edition of Siemens MAGNETOM Flash

Nov 14, 2024, 5:00 PM EST - 1 year ago

Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st

Oct 10, 2024, 7:00 AM EDT - 1 year ago

Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 27, 2024, 6:57 AM EDT - 1 year ago

Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes

Sep 13, 2024, 8:30 AM EDT - 1 year ago

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Sep 12, 2024, 6:57 AM EDT - 1 year ago

Aclarion Provides Corporate Update on Nociscan AI Technology Milestones

Sep 10, 2024, 6:57 AM EDT - 1 year ago

Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial

Sep 5, 2024, 6:57 AM EDT - 1 year ago

Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market

Aug 29, 2024, 6:57 AM EDT - 1 year ago

Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

Aug 21, 2024, 7:57 AM EDT - 1 year ago

Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans

Aug 15, 2024, 9:48 AM EDT - 1 year ago

Aclarion to Present at August 20th Virtual Investor Summit Microcap Event

Aug 14, 2024, 8:08 AM EDT - 1 year ago

Aclarion Announces First Commercial Agreement in Michigan

Aug 13, 2024, 9:07 AM EDT - 1 year ago

Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK

Jun 26, 2024, 8:30 AM EDT - 1 year ago

Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

Jun 25, 2024, 8:30 AM EDT - 1 year ago

Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London

Apr 25, 2024, 9:14 AM EDT - 1 year ago

Aclarion's Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain

Feb 27, 2024, 3:22 PM EST - 1 year ago

Aclarion Announces Closing of $3.0 Million Public Offering

Feb 26, 2024, 9:15 AM EST - 1 year ago

Aclarion Announces Pricing of $3.0 Million Public Offering

Feb 5, 2024, 8:00 AM EST - 1 year ago

Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership

Jan 22, 2024, 8:00 AM EST - 2 years ago

Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD

Nov 27, 2023, 8:00 AM EST - 2 years ago

Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams

Nov 6, 2023, 8:00 AM EST - 2 years ago

Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD

Oct 25, 2023, 8:30 AM EDT - 2 years ago

Aclarion Announces Signing of Commercial Agreement With Porter Hospital, an AdventHealth facility, to Bring Nociscan Technology to Denver

Oct 24, 2023, 8:45 AM EDT - 2 years ago

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan

Aug 25, 2023, 4:10 PM EDT - 2 years ago

Aclarion, Inc. Announces Filing of Delayed 10-Q Quarterly Report

Jun 14, 2023, 11:27 AM EDT - 2 years ago

Aclarion Announces New Commercial Engagement with The Imaging Center, Grand Rapids, MI

Jun 8, 2023, 7:30 AM EDT - 2 years ago

Aclarion Announces Statistically Significant Nociscan® Cost-Effectiveness Abstract Presented at ISASS Annual Meeting

May 30, 2023, 7:30 AM EDT - 2 years ago

Aclarion Announces New Engagement with The London Clinic and London Spine Clinic

TurskaInTar Dec. 4 at 8:20 PM

$ACON close the gap already 😂 Going up anyway imo

0 · Reply

Pinecone_Tradingz_ Dec. 4 at 4:41 PM

0 · Reply

Putnik Dec. 4 at 4:08 PM

$ACON come on move for real!

0 · Reply

TurskaInTar Dec. 4 at 3:51 PM

$ACON $16 cash/share

0 · Reply

TurskaInTar Dec. 4 at 3:21 PM

$ACON SP should be double at least at this point, tech is working and teh market and the need is huge. And they have cash to make this work without new offerings.

0 · Reply

brptrader Dec. 4 at 3:13 PM

$ACON so some one or sombodies drove this to shit yesterday knowing news was coming out today...Nothing to see here, keep moving.

0 · Reply

TurskaInTar Dec. 4 at 3:06 PM

$ACON Publication in IJSS should speed up adaptation and expansion, and seems they are ready for it. Payer coverages for example with AXA has been in order for some time and so on...

0 · Reply

topstockalerts Dec. 4 at 2:58 PM

0 · Reply

TurskaInTar Dec. 4 at 2:55 PM

$ACON and after eight comes nine if I remember right

0 · Reply

TurskaInTar Dec. 4 at 2:36 PM

$ACON https://aclarion.com/aclarion-announces-publication-of-nociscan-article-in-special-pain-issue-of-the-international-journal-of-spine-surgery-ijss/

0 · Reply

Stock_Catcher Dec. 4 at 2:34 PM

$ACON now up 21% mentioned earlier

0 · Reply

Putnik Dec. 4 at 2:33 PM

$ACON

0 · Reply

TurskaInTar Dec. 4 at 2:31 PM

$ACON $8 coming

0 · Reply

Stock_Catcher Dec. 4 at 2:27 PM

$ACON thin one

0 · Reply

TurskaInTar Dec. 4 at 1:03 PM

$ACON PM looking good again

0 · Reply

TurskaInTar Dec. 4 at 11:50 AM

$ACON Gap closed, peace of mind here. Now lets go to 10-20.

0 · Reply

brptrader Dec. 3 at 3:53 PM

$ACON forming a big ol red fawq off

1 · Reply

carterlong05 Dec. 3 at 3:07 PM

$ACON If this platform ever grows to just 20–30M in annual revenue and gets a modest 3–5x sales multiple you’re talking about 60–150M valuation versus today’s micro cap range that’s the kind of R R profile that can change accounts

0 · Reply

Stock_Catcher Dec. 3 at 3:08 AM

Winner Wednesday Watchlist Pt. 10 $ACON $REPL $BLMZ $CAPR $RGTI Let's Bank Tomorrow 📈🎯

0 · Reply

Putnik Dec. 2 at 7:31 PM

$ACON $15 is cool with me!

0 · Reply

Huskersnsaints Dec. 2 at 6:08 PM

$ACON $AUUD I was wondering about that as well

0 · Reply

TurskaInTar Dec. 2 at 4:27 PM

$ACON or we can get going right now if the weak handed day traders are done

0 · Reply

Market Cap	4.81M
Revenue (ttm)	50,000.00
Net Income (ttm)	-6.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13,980.00%
Debt to Equity Ratio	0.00

Volume	188,418
Avg Vol	173,782
Day's Range	N/A - N/A
Shares Out	671,000.00
Stochastic %K	48%
Beta	1.43
Analysts	Sell
Price Target	$23.00